Perimeter Medical Imaging AI Announces First Commercial Installation of Perimeter S-Series OCT in North Texas and Ongoing Market Development Activities Across the U.S.
20 Dicembre 2021 - 2:30PM
Business Wire
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF)
(FSE:4PC) (“Perimeter” or the “Company”), a medical technology
company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
high unmet medical needs, today announced the first commercial
installation of its flagship Perimeter S-Series OCT system at a
North Texas hospital.
Perimeter S-Series is a novel medical imaging system that uses
Optical Coherence Tomography (OCT) to provide clinicians with
cross-sectional, real-time margin visualization (1-2 mm below the
surface) of an excised tissue specimen across a variety of tissue
types.
Jeremy Sobotta, Perimeter’s Chief Executive Officer stated, “We
are extremely pleased to announce the first commercial installation
of our Perimeter S-Series OCT system. This meaningful validation of
our ‘go-to-market’ strategy is an historic event for the Perimeter
team, our shareholders, the physicians with whom we collaborate,
and the patients in their care. By enhancing a surgeon’s ability to
visualize margins and microscopic tissue structures during a
procedure, we believe our ground-breaking imaging technology will
allow for optimal intraoperative decisions that increase the
precision of surgeries.”
Steve Sapot, Perimeter’s Chief Commercial Officer added, “This
installation of our Perimeter S-Series OCT device marks an
important milestone achieved by our commercial team, who are
connecting with innovators in healthcare institutions across the
U.S. Our market development activities continue to accelerate and
include extensive training and support for physicians. We are
confident that this margin visualization technology will give
surgeons added clarity to make better informed decisions real-time
during a procedure.”
About Perimeter S-Series OCT Cleared by the FDA with a
general tissue indication, Perimeter is bringing its S-Series
Optical Coherence Tomography (OCT) system to leading surgeons in
hospitals across the U.S., providing cross-sectional images of
tissues down to 2mm depth, with 10x higher image resolution than
standard x-ray and ultrasound. Perimeter S-Series OCT gives
physicians the ability to visualize microscopic tissue structures
at the point-of-care – during the primary surgery compared to days
later when pathology reports are available – which has the
potential to result in better long-term outcomes for patients and
lower costs to the healthcare system.
About Perimeter Medical Imaging AI, Inc. With
headquarters in Toronto, Canada and Dallas, Texas, Perimeter
Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical
technology company that is driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. The company’s ticker symbol
“PINK” is a reference to the pink ribbons used during Breast Cancer
Awareness Month, underscoring the company’s dedication to helping
surgeons, radiologists, and pathologists use Perimeter’s imaging
technology and AI in the fight against breast cancer, which is
estimated to account for 30% of all female cancer diagnoses this
year.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements This news release contains
statements that constitute “forward-looking information” within the
meaning of applicable Canadian securities legislation. In this news
release, words such as “may”, “would”, “could”, “will”, “likely”,
“believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and
similar words and the negative form thereof are used to identify
forward-looking statements. Forward-looking information may relate
to management’s future outlook and anticipated events or results
and may include statements or information regarding the future
financial position, business strategy and strategic goals,
competitive conditions, research and development activities,
projected costs and capital expenditures, research and clinical
testing outcomes, taxes and plans and objectives of, or involving,
Perimeter. Without limitation, information regarding the potential
benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and
Perimeter ImgAssist is forward-looking information. Forward-looking
statements should not be read as guarantees of future performance
or results, and will not necessarily be accurate indications of
whether, or the times at or by which, such future performance will
be achieved. No assurance can be given that any events anticipated
by the forward-looking information will transpire or occur.
Forward-looking information is based on information available at
the time and/or management’s good-faith belief with respect to
future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter’s control. Such forward-looking
statements reflect Perimeter’s current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties, and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter’s
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter’s
Management Discussion and Analysis for the year ended December 31,
2020, which is available on Perimeter’s SEDAR profile at
www.sedar.com, and could cause actual events or results to differ
materially from those projected in any forward-looking statements.
In particular, we note the risk that our technology may not achieve
the anticipated benefits in terms of surgical outcomes. Perimeter
does not intend, nor does Perimeter undertake any obligation, to
update or revise any forward-looking information contained in this
news release to reflect subsequent information, events, or
circumstances or otherwise, except if required by applicable
laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211220005238/en/
Shushu Feng Perimeter Medical Imaging AI, Inc. Direct:
647-339-7465 (PINK) Toll-free: 888-988-7465 (PINK)
investors@perimetermed.com
Grafico Azioni Simplify Exchang (NYSE:PINK)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Simplify Exchang (NYSE:PINK)
Storico
Da Giu 2023 a Giu 2024